Does dapagliflozin regress left ventricular hypertrophy in patients with type 2 diabetes? A prospective, double-blind, randomised, placebo-controlled study

BMC Cardiovascular Disorders

Volumn 17, Issue 1, 2017, Pages

  Brown, Alexander J M ^a   Lang, Chim ^a   McCrimmon, Rory ^a   Struthers, Allan ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Cardiac MRI; Diabetes; Left ventricular hypertrophy; Mechanistic trial; SGLT2 inhibitor

Indexed keywords

2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE;

BLOOD PRESSURE MONITORING; CLINICAL PROTOCOL; COMPLICATION; CONTROLLED STUDY; DIABETIC CARDIOMYOPATHY; DIAGNOSTIC IMAGING; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HUMAN; METHODOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PROOF OF CONCEPT; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SCOTLAND; TIME FACTOR; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; BENZHYDRYL COMPOUNDS; BLOOD PRESSURE MONITORING, AMBULATORY; CLINICAL PROTOCOLS; DIABETES MELLITUS, TYPE 2; DIABETIC CARDIOMYOPATHIES; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; GLUCOSIDES; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; HYPOGLYCEMIC AGENTS; MAGNETIC RESONANCE IMAGING; PROOF OF CONCEPT STUDY; PROSPECTIVE STUDIES; RESEARCH DESIGN; RISK FACTORS; SCOTLAND; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 85028350625     PISSN: None     EISSN: 14712261     Source Type: Journal    
DOI: 10.1186/s12872-017-0663-6     Document Type: Article

References (68)

1. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339(4):229-34.
2. Di Angelantonio E, Kaptoge S, Wormser D, Willeit P, Butterworth AS, Bansal N, et al. Association of Cardiometabolic Multimorbidity with Mortality. JAMA. 2015;314(1):52-60.
3. Mizamtsidi M, Paschou SA, Grapsa J, Vryonidou A. Diabetic cardiomyopathy: a clinical entity or a cluster of molecular heart changes? Eur J Clin Investig. 2016;46(11):947-53.
4. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes [UKPDS 35]: prospective observational study. BMJ Clinical Research Ed. 2000;321(7258):405-12.
5. Buse JB, Bigger JT, Byington RP, Cooper LS, Cushman WC, Friedewald WT, et al. Action to control cardiovascular risk in diabetes [ACCORD] trial: design and methods. Am J Cardiol. 2007;99(12a):21i-33i.
6. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560-72.
7. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129-39.
8. Zinman B, Lachin JM, Inzucchi SE. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2016;374(11):1094.
9. Dawson A, Morris AD, Struthers AD. The epidemiology of left ventricular hypertrophy in type 2 diabetes mellitus. Diabetologia. 2005;48(10):1971-9.
10. Cooper RS, Simmons BE, Castaner A, Santhanam V, Ghali J, Mar M. Left ventricular hypertrophy is associated with worse survival independent of ventricular function and number of coronary arteries severely narrowed. Am J Cardiol. 1990;65(7):441-5.
11. Liao Y, Cooper RS, McGee DL, Mensah GA, Ghali JK. The relative effects of left ventricular hypertrophy, coronary artery disease, and ventricular dysfunction on survival among black adults. JAMA. 1995;273(20):1592-7.
12. Artham SM, Lavie CJ, Milani RV, Patel DA, Verma A, Ventura HO. Clinical impact of left ventricular hypertrophy and implications for regression. Prog Cardiovasc Dis. 2009;52(2):153-67.
13. Mancia G, Carugo S, Grassi G, Lanzarotti A, Schiavina R, Cesana G, et al. Prevalence of left ventricular hypertrophy in hypertensive patients without and with blood pressure control: data from the PAMELA population. Pressioni Arteriose Monitorate E Loro Associazioni. Hypertension. 2002;39(3):744-9.
14. Fraser R. Studying genes and the development of cardiac hypertrophy: convenient intermediate phenotypes in man. J Hypertens. 2003;21(5):873-4.
15. Brown DW, Giles WH, Croft JB. Left ventricular hypertrophy as a predictor of coronary heart disease mortality and the effect of hypertension. Am Heart J. 2000;140(6):848-56.
16. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation. 1998;97(1):48-54.
17. Verdecchia P, Angeli F, Borgioni C, Gattobigio R, de Simone G, Devereux RB, et al. Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis. Am J Hypertens. 2003;16(11 Pt 1):895-9.
18. Verdecchia P, Angeli F, Gattobigio R, Sardone M, Pede S, Reboldi GP. Regression of left ventricular hypertrophy and prevention of stroke in hypertensive subjects. Am J Hypertens. 2006;19(5):493-9.
19. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA. 2004;292(19):2343-9.
20. Okin PM, Wachtell K, Devereux RB, Harris KE, Jern S, Kjeldsen SE, et al. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. JAMA. 2006;296(10):1242-8.
21. Okin PM, Devereux RB, Harris KE, Jern S, Kjeldsen SE, Julius S, et al. Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients. Ann Intern Med. 2007;147(5):311-9.
22. Wachtell K, Okin PM, Olsen MH, Dahlof B, Devereux RB, Ibsen H, et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE study. Circulation. 2007;116(7):700-5.
23. Koren MJ, Ulin RJ, Koren AT, Laragh JH, Devereux RB. Left ventricular mass change during treatment and outcome in patients with essential hypertension. Am J Hypertens. 2002;15(12):1021-8.
24. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan intervention for endpoint reduction in hypertension study [LIFE]: a randomised trial against atenolol. Lancet [London, England]. 2002;359(9311):1004-10.
25. Rutter MK, Parise H, Benjamin EJ, Levy D, Larson MG, Meigs JB, et al. Impact of glucose intolerance and insulin resistance on cardiac structure and function: sex-related differences in the Framingham heart study. Circulation. 2003;107(3):448-54.
26. Chaturvedi N, McKeigue PM, Marmot MG, Nihoyannopoulos P. A comparison of left ventricular abnormalities associated with glucose intolerance in African Caribbeans and Europeans in the UK. Heart. 2001;85(6):643-8.
27. Oberman A, Prineas RJ, Larson JC, LaCroix A, Lasser NL. Prevalence and determinants of electrocardiographic left ventricular hypertrophy among a multiethnic population of postmenopausal women [the Women's Health Initiative]. Am J Cardiol. 2006;97(4):512-9.
28. Ilercil A, Devereux RB, Roman MJ, Paranicas M, O'Grady MJ, Lee ET, et al. Associations of insulin levels with left ventricular structure and function in American Indians: the strong heart study. Diabetes. 2002;51(5):1543-7.
29. Devereux RB, de Simone G, Palmieri V, Oberman A, Hopkins P, Kitzman DW, et al. Relation of insulin to left ventricular geometry and function in African American and white hypertensive adults: the HyperGEN study. Am J Hypertens. 2002;15(12):1029-35.
30. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577-89.
31. UK Prospective Diabetes Study [UKPDS] Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes [UKPDS 33]. Lancet [London, England]. 1998;352(9131):837-53.
32. de Simone G, Devereux RB, Palmieri V, Roman MJ, Celentano A, Welty TK, et al. Relation of insulin resistance to markers of preclinical cardiovascular disease: the strong heart study. Nutr Metab Cardiovasc Dis. 2003;13(3):140-7.
33. Dorresteijn JA, Visseren FL, Spiering W. Mechanisms linking obesity to hypertension. Obes Rev. 2012;13(1):17-26.
34. Shubrook JH, Bokaie BB, Adkins SE. Empagliflozin in the treatment of type 2 diabetes: evidence to date. Drug Des Devel Ther. 2015;9:5793-803.
35. Kalra S. Sodium glucose co-transporter-2 [SGLT2] inhibitors: a review of their basic and clinical pharmacology. Diabetes Ther. 2014;5(2):355-66.
36. Nauck MA. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Des Devel Ther. 2014;8:1335-80.
37. Vasilakou D, Karagiannis T, Athanasiadou E, Mainou M, Liakos A, Bekiari E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013;159(4):262-74.
38. Oliva RV, Bakris GL. Blood pressure effects of sodium-glucose co-transport 2 [SGLT2] inhibitors. J Am Soc Hypertens. 2014;8(5):330-9.
39. Majewski C, Bakris GL. Blood pressure reduction: an added benefit of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes. Diabetes Care. 2015;38(3):429-30.
40. Chilton R, Tikkanen I, Cannon CP, Crowe S, Woerle HJ, Broedl UC, et al. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab. 2015;17(12):1180-93.
41. Rekhraj S, Gandy SJ, Szwejkowski BR, Nadir MA, Noman A, Houston JG, et al. High-dose allopurinol reduces left ventricular mass in patients with ischemic heart disease. J Am Coll Cardiol. 2013;61(9):926-32.
42. Baker WL, Smyth LR, Riche DM, Bourret EM, Chamberlin KW, White WB. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens. 2014;8(4):262-75. e9
43. Cherney DZ, Perkins BA, Soleymanlou N, Har R, Fagan N, Johansen OE, et al. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol. 2014;13:28.
44. Devereux RB, Roman MJ. Left ventricular hypertrophy in hypertension: stimuli, patterns, and consequences. Hypertens Res. 1999;22(1):1-9.
45. Bolinder J, Ljunggren O, Johansson L, Wilding J, Langkilde AM, Sjostrom CD, et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab. 2014;16(2):159-69.
46. Ferrannini E, Muscelli E, Frascerra S, Baldi S, Mari A, Heise T, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014;124(2):499-508.
47. Merovci A, Solis-Herrera C, Daniele G, Eldor R, Fiorentino TV, Tripathy D, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest. 2014;124(2):509-14.
48. Howard G, O'Leary DH, Zaccaro D, Haffner S, Rewers M, Hamman R, et al. Insulin sensitivity and atherosclerosis. The insulin resistance atherosclerosis study [IRAS] investigators. Circulation. 1996;93(10):1809-17.
49. Bolinder J, Ljunggren O, Kullberg J, Johansson L, Wilding J, Langkilde AM, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012;97(3):1020-31.
50. Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature. 2006;444(7121):881-7.
51. Ridderstrale M, Andersen KR, Zeller C, Kim G, Woerle HJ, Broedl UC. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol. 2014;2(9):691-700.
52. Cefalu WT, Leiter LA, Yoon KH, Arias P, Niskanen L, Xie J, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin [CANTATA-SU]: 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet [London, England]. 2013;382(9896):941-50.
53. Abassi Z, Leor J, Landa N, Younis F, Hollander K, Mayoux E, et al. Os 05-04 Empagliflozin exerts cardio- and Nephro-protective effects in Cohen-ROSENTHAL diabetic hypertensive rats. J Hypertens. 2016;34(Suppl 1 - ISH 2016 Abstract Book):e58-e9.
54. Empagliflozin Impact on Hemodynamics in Patients With Diabetes and Heart Failure - Tabular View - ClinicalTrials.gov 2017 [Available from: https://clinicaltrials.gov/ct2/show/record/NCT03030222?term=empagliflozin&rank=1.
55. SGLT2 Inhibition in Diabetes and Heart Failure - Full Text View - ClinicalTrials.gov 2017 [Available from: https://clinicaltrials.gov/ct2/show/NCT02862067?term=sglt+heart+failure&rank=1.
56. EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction [EMPEROR-Reduced] - Full Text View - ClinicalTrials.gov 2017 [Available from: https://clinicaltrials.gov/ct2/show/NCT03057977?term=empagliflozin&rank=41.
57. Dapagliflozin Effect on Symptoms and Biomarkers in Diabetes Patients With Heart Failure - Full Text View - ClinicalTrials.gov 2017 [Available from: https://clinicaltrials.gov/ct2/show/NCT02653482?term=sglt+heart+failure&rank=4.
58. Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure - Full Text View - ClinicalTrials.gov 2017 [Available from: https://clinicaltrials.gov/ct2/show/NCT03036124?term=DAPAGLIFLOZIN&rank=18.
59. Safety and Effectiveness of SGLT-2 Inhibitors in Patients With Heart Failure and Diabetes - Full Text View - ClinicalTrials.gov 2017 [Available from: https://clinicaltrials.gov/ct2/show/NCT02397421?term=sglt+heart+failure&rank=2.
60. Treatment of Diabetes in Patients With Systolic Heart Failure - Full Text View - ClinicalTrials.gov 2017 [Available from: https://clinicaltrials.gov/ct2/show/NCT02920918?term=sglt+heart+failure&rank=8.
61. Effects of Empagliflozin on Left Ventricular Diastolic Function Compared to Usual Care in Type 2 Diabetics - Tabular View - ClinicalTrials.gov 2017 [Available from: https://clinicaltrials.gov/ct2/show/record/NCT02932436?term=empagliflozin&rank=4.
62. SGLT2 Inhibition and Left Ventricular Mass - Full Text View - ClinicalTrials.gov 2017 [Available from: https://clinicaltrials.gov/ct2/show/NCT02728453?term=SGLT+HEART+FAILURE&rank=4.
63. Effects of Empagliflozin on Cardiac Structure in Patients With Type 2 Diabetes - Full Text View - ClinicalTrials.gov 2017 [Available from: https://clinicaltrials.gov/ct2/show/NCT02998970?term=empagliflozin&rank=8.
64. Dapagliflozin in Type 2 Diabetes or Pre-diabetes, and PRESERVED Ejection Fraction Heart Failure - Full Text View - ClinicalTrials.gov 2017 [Available from: https://clinicaltrials.gov/ct2/show/NCT03030235?term=SGLT+HEART+FAILURE&rank=7.
65. Does Dapagliflozin Regress Left Ventricular Hypertrophy In Patients With Type 2 Diabetes? - Full Text View - ClinicalTrials.gov 2017 [Available from: https://clinicaltrials.gov/ct2/show/NCT02956811.
66. Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events - Full Text View - ClinicalTrials.gov 2017 [Available from: https://clinicaltrials.gov/ct2/show/NCT01730534?term=DECLARE&rank=2.
67. CANVAS - CANagliflozin cardioVascular Assessment Study - Full Text View - ClinicalTrials.gov 2017 [Available from: https://clinicaltrials.gov/ct2/show/NCT01032629?term=CANVAS&rank=1.
68. Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy - Full Text View - ClinicalTrials.gov 2017 [Available from: https://clinicaltrials.gov/ct2/show/NCT02065791?term=CREDENCE&rank=2.